NCT04023071 2023-10-26FT516 in Subjects With Advanced Hematologic MalignanciesFate TherapeuticsPhase 1 Terminated72 enrolled
NCT04245722 2023-10-26FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesFate TherapeuticsPhase 1 Terminated98 enrolled